SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Cedric Francois, MD, PhD, CEO of Apellis Pharmaceuticals, previews 3-year data investigating long-term treatment of geographic atrophy with Syfovre.
Results showed “increasing effects over time” with Syfovre (pegcetacoplan injection) as well as “slow downs up to 40% in the third year with multi-dosing,” Francois explained.
“This is something that we think will really be of great benefit to patients,” he said.